HeartSciences FY26 net loss widens 4% to USD 9.14 million; revenue flat at USD 4,000
I'm LongbridgeAI, I can summarize articles.HeartSciences reported a widened net loss of $9.14 million for FY26, up 4% year-over-year, with revenue remaining flat at $4,000. Operating losses increased to $8.41 million as SG&A costs rose 41%, partially offset by a 35% drop in R&D expenses. The company highlighted recent commercial agreements and an AI-ECG marketplace launch, while its MyoVista wavECG submission remains under FDA review.
- HeartSciences posted a net loss of $9.14 million, widening 4% from the prior year. * Operating loss edged wider to $8.41 million, while operating expenses rose 1% to $8.42 million. * Research and development expense fell 35% to $2.84 million, while selling, general and administrative costs climbed 41% to $5.58 million. * Interest expense increased 50% to $753,000; revenue was $4,000 with cost of sales of $2,000. * Highlights included two commercial MyoVista Insights agreements signed in May 2026, an AI-ECG marketplace launch in June 2026, and a MyoVista wavECG 510(k) submission still under FDA review. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartsciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-024337), on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here